Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up

B. E. Johnson, D. C. Ihde, P. A. Bunn, B. Becker, T. Walsh, Z. R. Weinstein, M. J. Matthews, J. Whang-Peng, R. W. Makuch, A. Johnston-Early

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

We assessed the outcome in 252 patients with small-cell lung cancer 5 to 11 years after treatment with combination chemotherapy, with or without chest and cranial irradiation, in National Cancer Institute therapeutic trials from 1973 through 1978. Twenty-eight patients (11%) survived free of cancer for 30 months or more. Fourteen patients remain alive without evidence of cancer beyond 5 years (range, 6.4 to 11.3 years), and 7 patients have returned to a lifestyle similar to that before diagnosis. The other 14 patients who were cancer-free at 30 months have developed cancer or died; 6 patients had a relapse, 4 developed or died from non-small-cell lung cancer, and 4 died of unrelated causes. A few patients with small-cell lung cancer (5.6%) may be cured. Thirty-month, cancer-free survival is insufficient to show a cure. Although late toxicities are troublesome, they do not outweigh the benefits of prolonged survival and potential for cure with modern aggressive therapy in small-cell lung cancer.

Original languageEnglish
Pages (from-to)430-438
Number of pages9
JournalAnnals of Internal Medicine
Volume103
Issue number3
Publication statusPublished - Dec 4 1985
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Combination Drug Therapy
Recurrence
Neoplasms
Cranial Irradiation
Survival
National Cancer Institute (U.S.)
Non-Small Cell Lung Carcinoma
Life Style
Thorax
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. / Johnson, B. E.; Ihde, D. C.; Bunn, P. A.; Becker, B.; Walsh, T.; Weinstein, Z. R.; Matthews, M. J.; Whang-Peng, J.; Makuch, R. W.; Johnston-Early, A.

In: Annals of Internal Medicine, Vol. 103, No. 3, 04.12.1985, p. 430-438.

Research output: Contribution to journalArticle

Johnson, B. E. ; Ihde, D. C. ; Bunn, P. A. ; Becker, B. ; Walsh, T. ; Weinstein, Z. R. ; Matthews, M. J. ; Whang-Peng, J. ; Makuch, R. W. ; Johnston-Early, A. / Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. In: Annals of Internal Medicine. 1985 ; Vol. 103, No. 3. pp. 430-438.
@article{fb89321fb55545db9f61e70498b3f0cd,
title = "Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up",
abstract = "We assessed the outcome in 252 patients with small-cell lung cancer 5 to 11 years after treatment with combination chemotherapy, with or without chest and cranial irradiation, in National Cancer Institute therapeutic trials from 1973 through 1978. Twenty-eight patients (11{\%}) survived free of cancer for 30 months or more. Fourteen patients remain alive without evidence of cancer beyond 5 years (range, 6.4 to 11.3 years), and 7 patients have returned to a lifestyle similar to that before diagnosis. The other 14 patients who were cancer-free at 30 months have developed cancer or died; 6 patients had a relapse, 4 developed or died from non-small-cell lung cancer, and 4 died of unrelated causes. A few patients with small-cell lung cancer (5.6{\%}) may be cured. Thirty-month, cancer-free survival is insufficient to show a cure. Although late toxicities are troublesome, they do not outweigh the benefits of prolonged survival and potential for cure with modern aggressive therapy in small-cell lung cancer.",
author = "Johnson, {B. E.} and Ihde, {D. C.} and Bunn, {P. A.} and B. Becker and T. Walsh and Weinstein, {Z. R.} and Matthews, {M. J.} and J. Whang-Peng and Makuch, {R. W.} and A. Johnston-Early",
year = "1985",
month = "12",
day = "4",
language = "English",
volume = "103",
pages = "430--438",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up

AU - Johnson, B. E.

AU - Ihde, D. C.

AU - Bunn, P. A.

AU - Becker, B.

AU - Walsh, T.

AU - Weinstein, Z. R.

AU - Matthews, M. J.

AU - Whang-Peng, J.

AU - Makuch, R. W.

AU - Johnston-Early, A.

PY - 1985/12/4

Y1 - 1985/12/4

N2 - We assessed the outcome in 252 patients with small-cell lung cancer 5 to 11 years after treatment with combination chemotherapy, with or without chest and cranial irradiation, in National Cancer Institute therapeutic trials from 1973 through 1978. Twenty-eight patients (11%) survived free of cancer for 30 months or more. Fourteen patients remain alive without evidence of cancer beyond 5 years (range, 6.4 to 11.3 years), and 7 patients have returned to a lifestyle similar to that before diagnosis. The other 14 patients who were cancer-free at 30 months have developed cancer or died; 6 patients had a relapse, 4 developed or died from non-small-cell lung cancer, and 4 died of unrelated causes. A few patients with small-cell lung cancer (5.6%) may be cured. Thirty-month, cancer-free survival is insufficient to show a cure. Although late toxicities are troublesome, they do not outweigh the benefits of prolonged survival and potential for cure with modern aggressive therapy in small-cell lung cancer.

AB - We assessed the outcome in 252 patients with small-cell lung cancer 5 to 11 years after treatment with combination chemotherapy, with or without chest and cranial irradiation, in National Cancer Institute therapeutic trials from 1973 through 1978. Twenty-eight patients (11%) survived free of cancer for 30 months or more. Fourteen patients remain alive without evidence of cancer beyond 5 years (range, 6.4 to 11.3 years), and 7 patients have returned to a lifestyle similar to that before diagnosis. The other 14 patients who were cancer-free at 30 months have developed cancer or died; 6 patients had a relapse, 4 developed or died from non-small-cell lung cancer, and 4 died of unrelated causes. A few patients with small-cell lung cancer (5.6%) may be cured. Thirty-month, cancer-free survival is insufficient to show a cure. Although late toxicities are troublesome, they do not outweigh the benefits of prolonged survival and potential for cure with modern aggressive therapy in small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021971351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021971351&partnerID=8YFLogxK

M3 - Article

C2 - 2992337

AN - SCOPUS:0021971351

VL - 103

SP - 430

EP - 438

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -